Chorobowość łuszczycowego zapalenia stawów w Polsce i koszty generowane przez chorych z ŁZS w systemie publicznej opieki zdrowotnej
Data nadesłania: 02-09-2016
Data ostatniej rewizji: 25-10-2016
Data akceptacji: 09-11-2016
Data publikacji online: 30-12-2016
Data publikacji: 30-12-2016
Reumatologia 2016;54(6):278-284
Objective: The objective of the study was to analyse the prevalence of psoriatic arthritis (PsA) in Poland and to assess the costs generated by treatment of PsA patients in the system of public healthcare.
Material and methods: The analysis was based on the database of the public payer, the National Health Fund (NFZ). PsA was defined by the diagnostic ICD-10 codes M07 (Enteropathic arthropathies) and L40.5 (Psoriatic arthropathies). The estimate of the costs was based on the reports submitted to the NFZ by health service providers. The prevalence rates were calculated using the NFZ data and the population estimates from the Central Statistical Office of Poland (GUS).
Results: In 2015, the prevalence of PsA (ICD-10: L40.5 and M07) in Poland was 3.2 per 10 000 population (3.7 in women and 2.6 in men). In 2015, nearly 7.3 thousand patients with the diagnosis of M07 and 6.3 thousand patients with the diagnosis of L40.5 received healthcare benefits. Women accounted for 60.6% of those patients. Nearly three fourths of PsA patients were aged 40 to 69 years with the median age of 54 years (56 years in women and 50 years in men). Between 2008 and 2015 the NFZ expenditure on the treatment of PsA increased from 6.6 million Polish zloty (PLN) (1.9 million EUR) to PLN 50.8 million (12.1 million EUR). In the same period, the number of PsA patients increased from 3.4 thousand to 11.9 thousand. In 2015, the mean cost of treatment per PsA patient was PLN 3.8 thousand.
Conclusions: The PsA prevalence rates estimated by the authors from the NFZ database are clearly lower than those derived from studies in other European countries, which may suggest that the actual number of PsA patients in Poland may be underestimated. Still the number of patients treated for PsA increased nearly 3.5-fold during 2008–2015, when the cost of PsA treatment rose more than 7 times.
Stanisławska-Biernat E, Świerkot J, Tłustochowicz W. Spondyloartropatie. Reumatologia 2012; 50: 93-102.
Olivieri I, D’Angelo S, Gilio M, et al. Relationship of Psoriatic Arthritis to Other Spondyloarthritides. J Rheumatol Suppl 2015; 93: 33-35.
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a lar-ge international study. Arthritis Rheum 2006; 54: 2665-2673.
Queiro R, Moreno P, Sarasqueta C, et al. Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome and psoriatic arthritis exhibit a different immunogenetic profile. Clin Exp Rheumatol 2008; 26: 125-128.
Queiro-Silva R, Torre-Alonso JC, Tinturé-Eguren T, et al. The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis. Scand J Rheumatol 2004; 33: 318-322.
Ho Pauline YPC, Barton A, Worthington J, et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis 2008; 67: 677-682.
Adizie T, Moots RJ, Hodkinson B, et al. Inflammatory arthritis in HIV positive patients: A practical guide. BMC Infect Dis 2016; 16: 100.
Manasson J, Scher JU. Spondyloarthritis and the microbiome: new insights from an ancient hypothesis. Curr Rheumatol Rep 2015; 17: 10.
Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012; 71: 1273-1277.
Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis:.
a population-based study. Arthritis Rheum 2009; 61: 233-239.
Ogdie A, Gelfand JM. Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence. Curr Rheumatol Rep 2015; 17: 64.
Huang YP, Wang Yh, Pan SL. Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis – a population-based longitudinal follow-up study. PloS One 2013; 8: e64155.
Daïen CI, Sellam J. Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response. RMD Open 2015; 1: e000012.
Anagnostopoulos I, Zinzaras E, Alexiou I, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskeletal Dis 2010; 11: 98.
Social Insurance Institution (2015) Statistical Portal http://www.psz.zus.pl/Default..... Accessed 30 June 2016 Polish.
Population. Status and structure of the population and its migration by administrative regions http://stat.gov.pl/obszary-tem... Accessed 26 June 2016 Polish.
Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology 2013; 52: 568-575.
Jordan KP, Jöud A, Bergknut C, et al. International comparisons of the consultation prevalence of musculoskeletal conditions using population-based healthcare data from England and Sweden. Ann Rheum Dis 2014; 73: 212-218.
Lofvendahl S, Theander E, Svensson A, et al. Validity of Diagnostic Codes and Prevalence of Physician-Diagnosed Psoriasis and Psoriatic Arthritis in Southern Sweden – A Population-Based Register Study. PLoS ONE 2014; 9: e98024.
Śliwczyński A, Raciborski F, Kłak A, et al. Prevalence of ankylosing spondylitis in Poland and costs generated by AS patients in the public healthcare system. Rheumatol Int 2015; 35: 1361-1367.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top